Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2020-11-18 Regulatory Filings
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PR - PHN agreement Greece, Cyprus and Mauritius 18_11_2020
Regulatory Filings Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. received on November 18, 2020, identified by the header "Informazione Regolamentata n. 20106-44-2020". The subject is "Mauritius 18_11_2020 PR - PHN agreement Greece, Cyprus and". The content details the signing of new international distribution agreements for Cetilar® and SiderAL® products in Greece, Cyprus, and Mauritius. This type of announcement, detailing specific business developments, agreements, or material operational news that is not a full financial report (like 10-K or IR) or a standard earnings release (ER), typically falls under general regulatory announcements or specific corporate actions. Since it is a press release announcing strategic business developments (new distribution contracts), and it doesn't fit perfectly into categories like DIV, CAP, or M&A, it is best classified as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a report. Given the content is the announcement itself (a press release detailing new agreements), RNS is the most appropriate general regulatory category for material, non-standard disclosures.
2020-11-18 English
CS - PHN accordo Grecia, Cipro e Mauritius 18_11_2020
Regulatory Filings Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. filed on November 18, 2020, identified by the header "Informazione Regolamentata n. 20106-43-2020" and the type "REGEM". The subject ("Oggetto") is "CS - PHN accordo Grecia, Cipro e Mauritius 18_11_2020", and the content details new international distribution agreements for their products (Cetilar® and SiderAL® Forte). This type of announcement, which communicates specific, material business developments (like new contracts or partnerships) that are not standard periodic financial reports (10-K, IR, ER), typically falls under general regulatory announcements or specific corporate actions. Since it is a press release announcing a significant business event (new distribution deals) and not a formal financial statement, management discussion, or director dealing, it best fits the general category for regulatory announcements that don't have a more specific code. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback category) is the most appropriate classification for this type of market-sensitive news release, especially since it is not a formal financial report or a specific corporate action like a dividend or share transaction.
2020-11-18 Italian
CS - PHN registrazione marchi USA
Investor Presentation Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated November 11, 2020, identified by the header 'Informazione Regolamentata n. 20106-42-2020'. The subject ('Oggetto') is 'CS - PHN registrazione marchi USA' (Press Release - PHN US trademark registration). The content explicitly announces the registration of the Cetilar® and SiderAL® trademarks in the USA by the USPTO. This is a specific corporate announcement regarding intellectual property and business development, not a periodic financial report (like 10-K or IR), a transcript (CT), or a general regulatory filing (RNS). Since it is a specific announcement of a corporate event/development that doesn't fit the other specific categories (like M&A, Dividend, Management Change), it falls best under the general 'Regulatory Filings' (RNS) category, as it is a formal disclosure to the market about a material event, or potentially 'LTR' if viewed as protecting assets, but RNS is the most appropriate general disclosure category when a more specific one isn't available for IP news. Given the options, RNS serves as the best fit for a material, non-financial, non-management specific corporate update.
2020-11-11 Italian
CS - PHN risultati 30 settembre 2020
Earnings Release Classification · 1% confidence The document is a formal communication from Pharmanutra S.p.A. dated November 9, 2020, titled 'CS - PHN risultati 30 settembre 2020' (Press Release - PHN results September 30, 2020). It presents key financial highlights (Revenues, EBITDA, Net Income, Net Financial Position) for the nine months ended September 30, 2020, comparing them to the previous year. It explicitly states that the Board of Directors examined and approved the 'relazione finanziaria consolidata al 30 settembre 2020' (consolidated financial report as of September 30, 2020). Although it mentions the full report is attached ('Vedi allegato') and discusses the transition to the STAR segment, the core content provided is the summary announcement of the period's financial performance, which aligns perfectly with the definition of an Earnings Release (ER). It is not the full, comprehensive Interim/Quarterly Report (IR) itself, but the initial announcement of the results. 9M 2020
2020-11-09 Italian
CS PharmaNutra aggiornamento calendario eventi 2020
Report Publication Announcement Classification · 1% confidence The document is a formal communication ('Informazione Regolamentata') from Pharmanutra S.p.A. dated November 6, 2020. The subject ('Oggetto') is 'CS PharmaNutra aggiornamento calendario eventi 2020' (Update to the 2020 corporate events calendar). The text explicitly states that the company is communicating an update to the financial calendar, specifically noting a Board of Directors meeting scheduled for November 9, 2020, to approve the consolidated financial report as of September 30, 2020. Since this document is an announcement *about* the release schedule of future financial reports (specifically mentioning the upcoming approval of the Q3/9-month report), and it is a short regulatory notice, it fits the definition of a Report Publication Announcement (RPA). It is not the full report itself (like 10-K or IR), nor is it the earnings release (ER) which would contain the actual results.
2020-11-06 Italian
CS - PHARMANUTRA lancia il nuovo Cetilar Tape
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by the structure, the subject line 'CS - PHARMANUTRA lancia il nuovo Cetilar Tape', and the date/time stamp typical of regulatory dissemination systems like AIM-Italia). The content announces the launch of a new product ('Cetilar Tape') and provides details about its features and market availability. This is a general corporate announcement regarding a business development/product update, not a formal financial report (like 10-K, IR, ER) or a specific regulatory filing like insider trading (DIRS) or capital change (CAP/SHA). Since it is a general corporate communication about a business event, and it is not a transcript (CT), management discussion (MDA), or a formal report announcement (RPA), the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially a specific type if one fits better. Given the focus is on a new product launch, it doesn't fit the defined categories well, making RNS the best general fit for non-financial, non-management specific news releases, although it is a specific product announcement. However, looking closely at the definitions, none perfectly capture a 'New Product Launch Announcement'. It is not an Earnings Release (ER), nor a Management Report (MDA). It is a general communication. RNS is the fallback for miscellaneous filings. The document length (6600 chars) is substantial enough that it is the announcement itself, not just a notice to download an attachment (which would favor RPA). Therefore, RNS is the most suitable general regulatory announcement category.
2020-11-03 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.